Porphyria cutanea tarda: kockázati tényezó-e a haemochromatosis gén (HFE)-mutáció és a hepatitis-C vírus (HCV)-infekció?

Z. Nagy, F. Kószó, A. Pár, A. Nagy, M. Horányi, M. Morvay, A. Dobozy, G. Mózsik

Research output: Article

1 Citation (Scopus)

Abstract

As it is not clear whether mutations in hemochromatosis gene (HFE) and hepatitis C virus (HCV) act independently in the pathogenesis of porphyria cutanea tarda (PCT), and prevalence of both risk factors reveals a great variety in different parts of the world, PCT patients from our Central East European country were investigated for this aspect. The occurrence of the C282Y and H63D mutations in HFE gene were determined in 19 PCT patients and compared with the reported control frequencies. Furthermore, the presence of HCV infection was determined and related to the patients' HFE status. The C282Y mutation was found in 3/19 cases (one patient was homozygous and two heterozygous), with an 10.5% allele frequency (vs. 3.8% control) (p <0.05). Five patients were heterozygous for the H63D mutation, allele frequency 13.1%, which did not differ from the reported control prevalence of 12.3%. Six patients (31.7%) were HCV-RNA positive, out of the six one was heterozygous for H63D mutation and one was compound heterozygous. HCV infection and HFE C282Y mutations may probably be independent predisposing factors for development of PCT in Hungarian patients.

Original languageHungarian
Pages (from-to)2031-2034
Number of pages4
JournalOrvosi Hetilap
Volume141
Issue number37
Publication statusPublished - szept. 10 2000

Fingerprint

Porphyria Cutanea Tarda
Hemochromatosis
Virus Diseases
Hepacivirus
Mutation
Genes
Gene Frequency
Mutation Rate
Causality
RNA

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{7ce29a60cd3d4612b6600fdbb40c58b7,
title = "Porphyria cutanea tarda: kock{\'a}zati t{\'e}nyez{\'o}-e a haemochromatosis g{\'e}n (HFE)-mut{\'a}ci{\'o} {\'e}s a hepatitis-C v{\'i}rus (HCV)-infekci{\'o}?",
abstract = "As it is not clear whether mutations in hemochromatosis gene (HFE) and hepatitis C virus (HCV) act independently in the pathogenesis of porphyria cutanea tarda (PCT), and prevalence of both risk factors reveals a great variety in different parts of the world, PCT patients from our Central East European country were investigated for this aspect. The occurrence of the C282Y and H63D mutations in HFE gene were determined in 19 PCT patients and compared with the reported control frequencies. Furthermore, the presence of HCV infection was determined and related to the patients' HFE status. The C282Y mutation was found in 3/19 cases (one patient was homozygous and two heterozygous), with an 10.5{\%} allele frequency (vs. 3.8{\%} control) (p <0.05). Five patients were heterozygous for the H63D mutation, allele frequency 13.1{\%}, which did not differ from the reported control prevalence of 12.3{\%}. Six patients (31.7{\%}) were HCV-RNA positive, out of the six one was heterozygous for H63D mutation and one was compound heterozygous. HCV infection and HFE C282Y mutations may probably be independent predisposing factors for development of PCT in Hungarian patients.",
author = "Z. Nagy and F. K{\'o}sz{\'o} and A. P{\'a}r and A. Nagy and M. Hor{\'a}nyi and M. Morvay and A. Dobozy and G. M{\'o}zsik",
year = "2000",
month = "9",
day = "10",
language = "Hungarian",
volume = "141",
pages = "2031--2034",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "37",

}

TY - JOUR

T1 - Porphyria cutanea tarda

T2 - kockázati tényezó-e a haemochromatosis gén (HFE)-mutáció és a hepatitis-C vírus (HCV)-infekció?

AU - Nagy, Z.

AU - Kószó, F.

AU - Pár, A.

AU - Nagy, A.

AU - Horányi, M.

AU - Morvay, M.

AU - Dobozy, A.

AU - Mózsik, G.

PY - 2000/9/10

Y1 - 2000/9/10

N2 - As it is not clear whether mutations in hemochromatosis gene (HFE) and hepatitis C virus (HCV) act independently in the pathogenesis of porphyria cutanea tarda (PCT), and prevalence of both risk factors reveals a great variety in different parts of the world, PCT patients from our Central East European country were investigated for this aspect. The occurrence of the C282Y and H63D mutations in HFE gene were determined in 19 PCT patients and compared with the reported control frequencies. Furthermore, the presence of HCV infection was determined and related to the patients' HFE status. The C282Y mutation was found in 3/19 cases (one patient was homozygous and two heterozygous), with an 10.5% allele frequency (vs. 3.8% control) (p <0.05). Five patients were heterozygous for the H63D mutation, allele frequency 13.1%, which did not differ from the reported control prevalence of 12.3%. Six patients (31.7%) were HCV-RNA positive, out of the six one was heterozygous for H63D mutation and one was compound heterozygous. HCV infection and HFE C282Y mutations may probably be independent predisposing factors for development of PCT in Hungarian patients.

AB - As it is not clear whether mutations in hemochromatosis gene (HFE) and hepatitis C virus (HCV) act independently in the pathogenesis of porphyria cutanea tarda (PCT), and prevalence of both risk factors reveals a great variety in different parts of the world, PCT patients from our Central East European country were investigated for this aspect. The occurrence of the C282Y and H63D mutations in HFE gene were determined in 19 PCT patients and compared with the reported control frequencies. Furthermore, the presence of HCV infection was determined and related to the patients' HFE status. The C282Y mutation was found in 3/19 cases (one patient was homozygous and two heterozygous), with an 10.5% allele frequency (vs. 3.8% control) (p <0.05). Five patients were heterozygous for the H63D mutation, allele frequency 13.1%, which did not differ from the reported control prevalence of 12.3%. Six patients (31.7%) were HCV-RNA positive, out of the six one was heterozygous for H63D mutation and one was compound heterozygous. HCV infection and HFE C282Y mutations may probably be independent predisposing factors for development of PCT in Hungarian patients.

UR - http://www.scopus.com/inward/record.url?scp=0034633131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034633131&partnerID=8YFLogxK

M3 - Article

C2 - 11037612

AN - SCOPUS:0034633131

VL - 141

SP - 2031

EP - 2034

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 37

ER -